Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
about
Analysis of the genome to personalize therapy for melanomaDe novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromesGenetics and biology of pancreatic ductal adenocarcinomaThe PI3K/AKT Pathway and Renal Cell CarcinomaPhosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerWill kinase inhibitors make it as glioblastoma drugs?Phosphoinositides: tiny lipids with giant impact on cell regulationStructure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory MechanismRegulation of lipid binding underlies the activation mechanism of class IA PI3-kinasesWill targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?Integrative genomic profiling of human prostate cancerRegulation of the PI3K pathway through a p85α monomer-homodimer equilibriumPI3K and cancer: lessons, challenges and opportunitiesDirect positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.The determinants of head and neck cancer: Unmasking the PI3K pathway mutationsDynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.SHORT syndrome in a two-year-old girl - case report.NRMT2 is an N-terminal monomethylase that primes for its homologue NRMT1.Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome.Role of phosphatidylinositol 3-kinase in friend spleen focus-forming virus-induced erythroid disease.Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alphaA human immunodeficiency caused by mutations in the PIK3R1 gene.PI3K: from the bench to the clinic and back.Structural basis of nSH2 regulation and lipid binding in PI3Kα.A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer libraryINPP5E interacts with AURKA, linking phosphoinositide signaling to primary cilium stabilityHeterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3KPIK3R1 underexpression is an independent prognostic marker in breast cancer.Somatic mutations of PIK3R1 promote gliomagenesis.Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K)Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase.Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status.Direct association of heat shock protein 20 (HSPB6) with phosphoinositide 3-kinase (PI3K) in human hepatocellular carcinoma: regulation of the PI3K activity.PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancerIdentification of mutations in distinct regions of p85 alpha in urothelial cancer.Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.
P2860
Q24601008-F4B9F73F-97FD-4EFD-8110-09BE059FB0B0Q24627067-E0DA0855-3871-486D-BF9A-225319927849Q26765438-6AA7BD78-66CC-4485-9C15-9FC9D517723BQ26800216-995CD832-458A-4862-83F0-389B38B75E8AQ26862550-90CFECE9-5773-474E-80C6-598D0077978AQ27012684-785BC2AF-D1B3-43ED-A3BB-38E3D905C870Q27012953-44805219-48CD-40D9-BE58-32769DE79D64Q27667112-4ADA8387-FB9F-43C4-A41C-DF0B19B88F1FQ27675831-EB1DAD99-BC2E-4991-8FB4-59A9A513B9F4Q28078957-0C025A38-3CAA-4FF8-AF46-3F2E9BC04E24Q29619905-2EC79BA9-5F6E-462F-9459-359DC2C47C08Q30009133-95BD1B5D-C29D-4004-89CA-DB713CFEEC2EQ30080017-A9ADFD3E-6709-406D-AA37-F00F95091CF2Q30156937-D00B42B4-E2E8-409A-A882-5B5CD9D2AA1CQ30365726-283EDDDC-E550-452E-AA2C-5ACEA15855ADQ30538272-85572E7F-AC15-404A-89C1-87C565257916Q33556937-18ECA1EF-1746-4E54-9C71-6D33CC53FF62Q33640546-B64E8301-5586-462C-ABA7-361CC1A0A34EQ33862729-8FD06557-3A08-459B-BB37-E2856A6DDA39Q33871417-247A3B45-DC89-4F0D-8392-C3572A98CC1DQ33886553-A7C55AE1-E0E5-47F5-887A-BB3C034ADA9BQ33915396-83A27184-D79F-43B7-B094-48A5095AE008Q33964125-03EC20AD-8B59-471A-BDB9-9C3E17414514Q34100548-D70690C2-AC43-4275-9B2F-069250BDEFC5Q34129000-F48FE643-0A7C-45AA-95CA-F2D70F40B5D6Q34195495-C6D2E56F-315E-4174-B28B-EF0D6AE2E9F3Q34221876-A919EB25-94A9-44AA-8A43-0D41E16E7C71Q34358850-84A5DB2A-1B4B-42D4-A04E-67AED97CE5C6Q34372857-26D03F5C-37E8-4D07-BFD8-9E6EBFCA80A4Q34447855-51055247-85C2-429E-BD10-A0E629C34043Q34452767-B75780D7-EE75-4B76-B5F7-375BA8D4F6E6Q34478129-19A716C5-3BC1-4137-8E52-9430E357ECB7Q34482374-37623405-D25B-49F3-A336-C841AE929B03Q34601157-E270A4CF-84FF-4B65-BF00-928A66517663Q34755265-750C8251-1284-4B50-97DF-5DF48C6A275FQ35036588-22B80403-35C6-4157-9CC8-F4075DFBE6E5Q35040191-8F694187-8DD7-41C6-9544-20FA4B62471EQ35050913-156E3A5D-3624-458E-80E7-624AA7405E30Q35075756-B069D62E-B944-45B8-9870-7EC9D6752105Q35097324-BA105842-1825-4514-BA4A-CB40BFCFD212
P2860
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
@en
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
@nl
type
label
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
@en
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
@nl
prefLabel
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
@en
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
@nl
P2093
P2860
P50
P1433
P1476
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
@en
P2093
Bijay S Jaiswal
Denise M Kenski
Frederic J de Sauvage
Howard M Stern
Jeremy Stinson
Jiansheng Wu
Jonathan M Backer
Josh S Kaminker
Krista K Bowman
P2860
P304
P356
10.1016/J.CCR.2009.10.016
P577
2009-12-01T00:00:00Z